FDA approves Roche's oral giredestrant with everolimus for ESR1-mutated breast cancer
Reuters (via Yahoo) · · AI-summarised by FinFlash
The US FDA approved Roche's oral drug giredestrant combined with everolimus for adults with ER-positive, HER2-negative advanced or metastatic breast cancer carrying an ESR1 mutation that progressed after hormone therapy. In a late-stage study of 207 patients, the combination cut the risk of progression or death by 62%, with median progression-free survival of 10 months versus 5.5 months for the comparator. The FDA also authorised a companion blood test to identify eligible patients.
So What?
The approval adds a new oral endocrine franchise for Roche in a crowded breast cancer market and pressures rival oral SERD developers; watch uptake and label expansion plans.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.